<p>新澤西州沃倫，2026 年 2 月 27 日（全球新聞通訊社）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（納斯達克：TVGN）今天宣佈已簽署一份非獨佔性、非約束性的意向書（“LoI”），以評估與一家知名全球合同研究組織（“CRO”）的潛在交易。如果交易達成，擬議的交易可能會擴展 Tevogen 的臨牀開發能力，並支持公司向一個產生收入的醫療企業的轉型。</p>
<p>Tevogen 的創始人兼首席執行官 Ryan Saadi 博士表示：“收購 CRO 的潛在交易可能會引入產生收入的服務能力，同時允許我們優化內部試驗執行。我們相信這種運營控制與服務收入的結合可能會增強盈利可見性，支持更具資本效率的增長模式，並提高患者的可負擔性。”</p>
<p>擬議的交易仍需滿足其他條件，包括盡職調查的完成、最終文件的談判和簽署、所需的批准以及滿足慣例的成交條件。</p>
<p>Tevogen 還在積極考慮其他交易，重點關注生命科學相關業務；然而，無法保證任何此類交易會達成。</p>
<p><strong>關於 Tevogen</strong></p>
<p>Tevogen 是一家社會整合的醫療企業，建立在可負擔性、效率和科學嚴謹的原則之上。該公司利用人工智能和精準 T 細胞治療平台，以患者為中心和成本控制的運營模式，以及與全球技術領導者的合作，支持在多個治療領域開發先進的、拯救生命的療法和可擴展的解決方案，以改善更廣泛的醫療系統。</p>
<p>Tevogen Bio 是公司的主要項目，已完成一項概念驗證臨牀試驗，證明其單 HLA 限制、基因未修飾的異體 T 細胞的潛力。Tevogen Bio 的產品線涵蓋病毒學、腫瘤學和神經學，基於公司的專有 ExacTcell™平台構建。</p>
<p>Tevogen.AI 旨在通過加速目標檢測、幫助降低失敗率以及通過專有預測技術支持優化臨牀試驗設計來轉變藥物開發。該平台利用來自領先技術提供商（包括微軟和 Databricks）的雲和數據服務，以推進其長期目標，即預測任何給定蛋白質-HLA 組合的蛋白質組，從而實現快速且成本高效的治療發現。</p>
<p>Tevogen 正在探索未來的戰略舉措，可能包括國內仿製藥、生物類似藥、醫療設備和創新保險解決方案，以服務於醫療提供者。這些項目共同反映了 Tevogen 的使命，即通過更快、更高效和更公平的醫療模式推動可持續創新，擴大患者的可及性。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含某些前瞻性聲明，包括但不限於與潛在交易及其潛在利益相關的聲明；Tevogen 對其研究和製造能力的計劃；對未來增長的預期；對醫療保健和生物製藥行業的預期；以及 Tevogen 對其產品候選者的開發、潛在利益和患者獲取的預期。前瞻性聲明有時可以通過諸如 “可能”、“可以”、“將”、“期望”、“預期”、“可能”、“潛在”、“目標”、“機會”、“項目”、“相信”、“未來” 等詞語及其反義詞來識別。這些聲明基於管理層截至本新聞稿日期的期望、假設、估計、預測和信念，並受到許多因素的影響，包括已知和未知的風險、延遲、不確定性以及其他不在公司控制範圍內的因素，這些因素可能導致公司的實際結果、表現或成就與這些前瞻性聲明所表達或暗示的結果、表現或其他期望存在重大差異。</p>
<p>可能導致實際結果、表現或成就與前瞻性聲明中所表達或暗示的內容存在差異的因素包括但不限於：與擬議交易的盡職調查和談判相關的固有風險；交易可能無法以有利條款完成或根本無法完成的風險；交易的預期收益可能無法及時實現或根本無法實現的風險；Tevogen 競爭市場的變化，包括其競爭格局、技術演變或監管變化；國內和全球經濟狀況的變化；Tevogen 可能無法執行其增長戰略或在管理增長和擴展運營方面遇到困難的風險；Tevogen 可能無法開發和維持有效內部控制的風險；未能實現 Tevogen 的商業化和發展計劃以及識別和實現額外機會的風險，這可能受到競爭、Tevogen 能否經濟地增長和管理增長以及招聘和留住關鍵員工等因素的影響；Tevogen 可能未能跟上快速技術發展的步伐，以提供新穎和創新的產品和服務，或在不成功的新產品和服務上進行大量投資的風險；Tevogen 將需要籌集額外資金以充分實現其商業計劃的風險；與開發、許可或收購新療法相關的風險；與 Tevogen 業務相關的監管訴訟或程序的風險；在執行、成本和完成臨牀前研究和臨牀試驗中固有的不確定性；與監管審查、批准和商業開發相關的風險；與知識產權保護相關的風險；Tevogen 的有限運營歷史；以及在 Tevogen 最近的 10-K 表格年度報告和隨後向 SEC 提交的文件中討論或引用的因素。</p>
<p>您不應過度依賴前瞻性聲明，因為這些聲明僅在作出時有效。Tevogen 不承擔更新任何前瞻性聲明的義務，除非適用法律要求。</p>
<p><strong>聯繫方式</strong></p>
<p>Tevogen Bio 公共關係部</p>
<p>電話：1 877 TEVOGEN，分機 701</p>
<p>Communications@Tevogen.com</p>
<p>與此公告相關的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/aa22e271-a8d5-479c-b655-0c3be590c7b7 獲取。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk16QTJOeU0zTkRVNU56QTRJekl5T0RrNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk16QTJOeU0zTkRVNU56QTRJekl5T0RrNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmQ1NDYyNTItZTY1Yi00ZjE4LTkxODktYmRhZDUxODViZDY1LTEzMDE0NjctMjAyNi0wMi0yNy1lbg==/tiny/Tevogen-Bio-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmQ1NDYyNTItZTY1Yi00ZjE4LTkxODktYmRhZDUxODViZDY1LTEzMDE0NjctMjAyNi0wMi0yNy1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

標普生物技術 3 倍做空 - Direxion

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

<p>Tevogen Bio Holdings Inc.（納斯達克代碼：TVGN）已簽署一份非約束性意向書，以評估潛在收購一家全球合同研究組織（CRO）。此舉旨在增強 Tevogen 的臨牀開發能力，並支持其轉型為一個產生收入的醫療企業。首席執行官 Ryan Saadi 博士強調，此次收購可能改善運營控制和服務收入，最終增強盈利可見性。該交易需經過盡職調查和其他慣常條件的審查。Tevogen 還在探索其他與生命科學相關的交易，但無法保證這些交易的完成</p>

<p>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organization (“CRO”). If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the Company’s evolution into a revenue-generating healthcare enterprise.</p>
<div class="lb-trans"><p>新澤西州沃倫，2026 年 2 月 27 日（全球新聞通訊社）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（納斯達克：TVGN）今天宣佈已簽署一份非獨佔性、非約束性的意向書（“LoI”），以評估與一家知名全球合同研究組織（“CRO”）的潛在交易。如果交易達成，擬議的交易可能會擴展 Tevogen 的臨牀開發能力，並支持公司向一個產生收入的醫療企業的轉型。</p>
</div><p>Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to optimize trial execution internally. We believe this combination of operational control and service revenue may strengthen earnings visibility, support a more capital-efficient growth model, and enhance patient affordability.”</p>
<div class="lb-trans"><p>Tevogen 的創始人兼首席執行官 Ryan Saadi 博士表示：“收購 CRO 的潛在交易可能會引入產生收入的服務能力，同時允許我們優化內部試驗執行。我們相信這種運營控制與服務收入的結合可能會增強盈利可見性，支持更具資本效率的增長模式，並提高患者的可負擔性。”</p>
</div><p>The proposed transaction remains subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>擬議的交易仍需滿足其他條件，包括盡職調查的完成、最終文件的談判和簽署、所需的批准以及滿足慣例的成交條件。</p>
</div><p>Tevogen is also actively considering other transactions with a focus on life sciences-related businesses; however, there can be no assurance that any such transaction will be consummated.</p>
<div class="lb-trans"><p>Tevogen 還在積極考慮其他交易，重點關注生命科學相關業務；然而，無法保證任何此類交易會達成。</p>
</div><p><strong>About Tevogen</strong></p>
<div class="lb-trans"><p><strong>關於 Tevogen</strong></p>
</div><p>Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.</p>
<div class="lb-trans"><p>Tevogen 是一家社會整合的醫療企業，建立在可負擔性、效率和科學嚴謹的原則之上。該公司利用人工智能和精準 T 細胞治療平台，以患者為中心和成本控制的運營模式，以及與全球技術領導者的合作，支持在多個治療領域開發先進的、拯救生命的療法和可擴展的解決方案，以改善更廣泛的醫療系統。</p>
</div><p>Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.</p>
<div class="lb-trans"><p>Tevogen Bio 是公司的主要項目，已完成一項概念驗證臨牀試驗，證明其單 HLA 限制、基因未修飾的異體 T 細胞的潛力。Tevogen Bio 的產品線涵蓋病毒學、腫瘤學和神經學，基於公司的專有 ExacTcell™平台構建。</p>
</div><p>Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.</p>
<div class="lb-trans"><p>Tevogen.AI 旨在通過加速目標檢測、幫助降低失敗率以及通過專有預測技術支持優化臨牀試驗設計來轉變藥物開發。該平台利用來自領先技術提供商（包括微軟和 Databricks）的雲和數據服務，以推進其長期目標，即預測任何給定蛋白質-HLA 組合的蛋白質組，從而實現快速且成本高效的治療發現。</p>
</div><p>Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.</p>
<div class="lb-trans"><p>Tevogen 正在探索未來的戰略舉措，可能包括國內仿製藥、生物類似藥、醫療設備和創新保險解決方案，以服務於醫療提供者。這些項目共同反映了 Tevogen 的使命，即通過更快、更高效和更公平的醫療模式推動可持續創新，擴大患者的可及性。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transaction and the potential benefits of the transaction; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本新聞稿包含某些前瞻性聲明，包括但不限於與潛在交易及其潛在利益相關的聲明；Tevogen 對其研究和製造能力的計劃；對未來增長的預期；對醫療保健和生物製藥行業的預期；以及 Tevogen 對其產品候選者的開發、潛在利益和患者獲取的預期。前瞻性聲明有時可以通過諸如 “可能”、“可以”、“將”、“期望”、“預期”、“可能”、“潛在”、“目標”、“機會”、“項目”、“相信”、“未來” 等詞語及其反義詞來識別。這些聲明基於管理層截至本新聞稿日期的期望、假設、估計、預測和信念，並受到許多因素的影響，包括已知和未知的風險、延遲、不確定性以及其他不在公司控制範圍內的因素，這些因素可能導致公司的實際結果、表現或成就與這些前瞻性聲明所表達或暗示的結果、表現或其他期望存在重大差異。</p>
</div><p>Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transaction; the risk that the transaction may not be consummated on favorable terms or at all; the risk that the expected benefits of the transaction may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.</p>
<div class="lb-trans"><p>可能導致實際結果、表現或成就與前瞻性聲明中所表達或暗示的內容存在差異的因素包括但不限於：與擬議交易的盡職調查和談判相關的固有風險；交易可能無法以有利條款完成或根本無法完成的風險；交易的預期收益可能無法及時實現或根本無法實現的風險；Tevogen 競爭市場的變化，包括其競爭格局、技術演變或監管變化；國內和全球經濟狀況的變化；Tevogen 可能無法執行其增長戰略或在管理增長和擴展運營方面遇到困難的風險；Tevogen 可能無法開發和維持有效內部控制的風險；未能實現 Tevogen 的商業化和發展計劃以及識別和實現額外機會的風險，這可能受到競爭、Tevogen 能否經濟地增長和管理增長以及招聘和留住關鍵員工等因素的影響；Tevogen 可能未能跟上快速技術發展的步伐，以提供新穎和創新的產品和服務，或在不成功的新產品和服務上進行大量投資的風險；Tevogen 將需要籌集額外資金以充分實現其商業計劃的風險；與開發、許可或收購新療法相關的風險；與 Tevogen 業務相關的監管訴訟或程序的風險；在執行、成本和完成臨牀前研究和臨牀試驗中固有的不確定性；與監管審查、批准和商業開發相關的風險；與知識產權保護相關的風險；Tevogen 的有限運營歷史；以及在 Tevogen 最近的 10-K 表格年度報告和隨後向 SEC 提交的文件中討論或引用的因素。</p>
</div><p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.</p>
<div class="lb-trans"><p>您不應過度依賴前瞻性聲明，因為這些聲明僅在作出時有效。Tevogen 不承擔更新任何前瞻性聲明的義務，除非適用法律要求。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>聯繫方式</strong></p>
</div><p>Tevogen Bio Communications</p>
<div class="lb-trans"><p>Tevogen Bio 公共關係部</p>
</div><p>T: 1 877 TEVOGEN, Ext 701</p>
<div class="lb-trans"><p>電話：1 877 TEVOGEN，分機 701</p>
</div><p>Communications@Tevogen.com</p>
<div class="lb-trans"><p>Communications@Tevogen.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/aa22e271-a8d5-479c-b655-0c3be590c7b7</p>
<div class="lb-trans"><p>與此公告相關的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/aa22e271-a8d5-479c-b655-0c3be590c7b7 獲取。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk16QTJOeU0zTkRVNU56QTRJekl5T0RrNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY2MzA2NyM3NDU5NzA4IzIyODk5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmQ1NDYyNTItZTY1Yi00ZjE4LTkxODktYmRhZDUxODViZDY1LTEzMDE0NjctMjAyNi0wMi0yNy1lbg==/tiny/Tevogen-Bio-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/ZmQ1NDYyNTItZTY1Yi00ZjE4LTkxODktYmRhZDUxODViZDY1LTEzMDE0NjctMjAyNi0wMi0yNy1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization  | TVGN Stock News

StockTitan

紐交所高增長板生物技術指數 ETF - First Trust

TEVOGEN BIO HOLDINGS INC C/WTS 14/02/2029 (TO PUR COM)

納斯達克生物科技指數 ETF - iShares Nasdaq

Invesco Nasdaq Biotechnology ETF

生物科技 ETF - VanEck Vectors

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

Tevogen Bio

Tevogen 簽署意向書以評估收購一家合同研究組織的潛力 | TVGN 股票新聞